The following criteria is provided for health care professionals.

Inclusion Criteria:

• Donors will be <55 years of age and in good health as approved by the National Marrow Donor Program (NMDP) donor and collection centers. Related donors will be < 70 years of age.
• Recipients will be <55 years, will have satisfactory organ function (excluding bone marrow) and will have a Karnofsky activity assessment >90% and will have:
  • Creatinine <2.0 mg/dl.
  • Bilirubin, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2 x normal.
  • Pulmonary function test and Carbon Monoxide Diffusing Capacity (DLCO) > 50% of normal.
  • Multi Gated Acquisition Scan (MUGA) >45% injection fraction.
• Recipients with unrelated donor matched at the HLA A, B, DRBI loci, or if < 35 years mismatched at a single HLA A or B, or DRBI locus.
• Umbilical cord blood (5) used as an unrelated stem cell source will provide > 2.0 x 10^7 cells/kg and will be matched at 4 - 6 of 6 HLA A, B, and DRBI loci. Cord blood grafts may include a single or pair of cord units depending on the cell dose.
• Partially matched related donors will be at least haploidentical (matched at >3 of 6 HLA A, B, DRB1 loci).
• Recipients will fall under one of the following disease categories
  • Chronic lymphocytic leukemia -- must have all three:
    • Rai Stage III/IV
    • Progression after previous Complete Response (CR) or Partial Response (PR) including purine antagonist (i.e. fludarabine).
    • Recent chemotherapy responsiveness
  • Advanced non-Hodgkin's lymphoma(NHL).
    • Low-grade NHL (Working Formulation A, B, C) following progression after initial therapy if asymptomatic at diagnosis (>CR2, >PR2; response duration < 1 year from last therapy) or if no CR was achieved (>PR1). At least one prior therapy of intermediate intensity (e.g. CHOP).
    • Mantle zone lymphoma after any progression following initial therapy (>CR1, > PR1). At least one prior therapy of intermediate intensity (e.g. CHOP).
    • Intermediate grade lymphoma (>PR2). Response duration <1 year from prior therapy.
    • High-grade Non-Hodgkin's Lymphoma (NHL) (IWF H, I, J) after initial therapy if >stage III at diagnosis; after any progression even if localized (stage I, II) at diagnosis with prior response duration < 1 year.
    • Recent chemotherapy responsiveness after treatment with > 3 intermediate intensity regimens.
  • Advanced Hodgkin's disease beyond PR2 (>CR3, >PR3).
    • Recent chemotherapy responsiveness
  • Multiple Myeloma (>CR2, >PR2) or after initial therapy if no prior PR.
    • Recent chemotherapy responsiveness
• Recipients will sign informed consent approved by the Committee on the Use of Human Subjects at the University of Minnesota.

Exclusion Criteria:

• No available histocompatible related donor; 2nd bone marrow transplant (BMT), HIV-1 positive; active uncontrolled infection; or resistant malignancy.